Broad-spectrum metastasis suppressing compounds and therapeutic uses thereof in human tumors.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 Nov 2023
21 Nov 2023
Historique:
received:
16
07
2023
accepted:
14
11
2023
medline:
23
11
2023
pubmed:
22
11
2023
entrez:
22
11
2023
Statut:
epublish
Résumé
Previously, we have identified a novel human metastasis-inducing lncRNA (named SKAI1BC), that suppresses the KAI1/CD82 metastasis-suppressing gene and is upregulated in triple negative breast cancer and melanoma derived cell lines. Modeling of the SKAI1BC lncRNA secondary structure and its potential interaction with Inforna compounds, led us to identify several compounds that might bind the SKAI1BC lncRNA. We found that these compounds inhibit metastasis invasion and cell migration in culture, in all eight types of solid human cancers tested: several of which are the most lethal and/or frequent human malignancies. Moreover, in most cases, the mechanism of action of several of our compounds involves enhancement of KAI1/CD82 RNA level depending on the specific compound and the human tumor type. With the epigenetic inactivation of KAI1/CD82 in at least ten additional solid human cancers, this implies a very good chance to broaden the spectrum of human cancers affected by our compounds. This is the first time that modeling of a large lncRNA (> 700 bp) secondary structure followed by its potential interaction with Inforna like compounds database has led to the identification of potential biologically active small molecule drugs.
Identifiants
pubmed: 37990044
doi: 10.1038/s41598-023-47478-x
pii: 10.1038/s41598-023-47478-x
pmc: PMC10663508
doi:
Substances chimiques
RNA, Long Noncoding
0
Kangai-1 Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20420Subventions
Organisme : NCI NIH HHS
ID : R01 CA249180
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM097455
Pays : United States
Organisme : NIH HHS
ID : CA249180; GM097455
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Cancer Metastasis Rev. 2015 Dec;34(4):619-33
pubmed: 26335499
NAR Genom Bioinform. 2022 Jan 14;4(1):lqab127
pubmed: 35047817
Nucleic Acids Res. 2023 Jan 6;51(D1):D587-D592
pubmed: 36300620
Methods. 2020 Nov 1;183:57-67
pubmed: 31711930
Cancer Res. 1987 Jun 15;47(12):3239-45
pubmed: 2438036
Br J Cancer. 2021 Aug;125(5):699-713
pubmed: 34172930
Nat Rev Genet. 2014 Jun;15(6):423-37
pubmed: 24776770
Cancers (Basel). 2021 Sep 06;13(17):
pubmed: 34503296
Protein Sci. 2019 Nov;28(11):1947-1951
pubmed: 31441146
Nucleic Acids Res. 2000 Jan 1;28(1):27-30
pubmed: 10592173
Anal Biochem. 2013 Aug 1;439(1):23-9
pubmed: 23583907
RNA. 2016 Dec;22(12):1808-1818
pubmed: 27852924
Nature. 2008 Jan 10;451(7175):202-6
pubmed: 18185590
Eur J Cell Biol. 2020 May;99(4):151075
pubmed: 32414588
ACS Chem Biol. 2016 Jun 17;11(6):1720-8
pubmed: 27097021
Algorithms Mol Biol. 2011 Nov 24;6:26
pubmed: 22115189
Trends Cancer. 2017 Jun;3(6):391-406
pubmed: 28670628
ACS Cent Sci. 2020 Oct 28;6(10):1713-1721
pubmed: 33140033
Nat Rev Drug Discov. 2021 Aug;20(8):629-651
pubmed: 34145432
PLoS Genet. 2008 Nov;4(11):e1000258
pubmed: 19008947
Invasion Metastasis. 1992;12(5-6):264-74
pubmed: 1284346
Nucleic Acids Res. 2019 Jan 8;47(D1):D135-D139
pubmed: 30371849
J Am Chem Soc. 2022 Nov 16;144(45):20815-20824
pubmed: 36322830
Front Oncol. 2021 Apr 27;11:659963
pubmed: 33987095
Angew Chem Int Ed Engl. 2018 Oct 1;57(40):13242-13247
pubmed: 30134013
ACS Chem Biol. 2019 Feb 15;14(2):223-235
pubmed: 30620551
Recent Pat Anticancer Drug Discov. 2018;13(3):292-301
pubmed: 29485010
J Am Chem Soc. 2018 Jun 6;140(22):6741-6744
pubmed: 29792692
J Oncol. 2021 Jul 9;2021:9924473
pubmed: 34306081
Chem Soc Rev. 2020 Oct 5;49(19):7167-7199
pubmed: 32975549
PeerJ. 2022 Nov 8;10:e14361
pubmed: 36389431
Bioinformatics. 2009 Aug 1;25(15):1974-5
pubmed: 19398448
Nat Chem Biol. 2014 Apr;10(4):291-7
pubmed: 24509821
Onco Targets Ther. 2017 Dec 06;10:5805-5816
pubmed: 29263677
Nat Rev Drug Discov. 2022 Oct;21(10):736-762
pubmed: 35941229
Int J Mol Sci. 2021 Mar 24;22(7):
pubmed: 33804856
Oncotarget. 2017 Jun 28;8(40):67538-67552
pubmed: 28978052
PeerJ. 2018 Dec 18;6:e6136
pubmed: 30627482